• 구독신청
  • My스크랩
  • 지면신문
FNTIMES 대한민국 최고 금융 경제지
ad

Samsung Biologics Hits Industry-First KRW 2 Trillion Operating Profit, Eyes KRW 3 Trillion Next [KFT Topic]

양현우 기자

yhw@fntimes.com

기사입력 : 2026-01-23 08:34 최종수정 : 2026-01-26 14:31

57% Year-Over-Year Growth Following Samsung Bioepis Spin-off
Securities Firms: "Growth Momentum to Continue This Year"

Samsung Biologics Plant 2. / Photo = Samsung Biologics

Samsung Biologics Plant 2. / Photo = Samsung Biologics

이미지 확대보기
[Korea Financial Times, Yang Hyunwoo] Samsung Biologics has written a new chapter in history. Following its industry-first breakthrough of KRW 1 trillion in operating profit in 2023, the company has reached the KRW 2 trillion milestone just two years later. The achievement is considered even more significant as it was accomplished after the spin-off from Samsung Bioepis. Given this growth trajectory, observers predict that annual operating profit of KRW 3 trillion is within reach.

Setting New Operating Profit Record in Two Years

According to Samsung Biologics on the 23nd, the company recorded an operating profit of KRW 2.0692 trillion (consolidated basis) last year. This represents a 57% increase from the previous year, making Samsung Biologics the first in the industry to surpass KRW 2 trillion in annual operating profit. During the same period, revenue grew 30% to KRW 4.557 trillion.

The strong performance was driven by the ramp-up of Plant 4 and improved operational efficiency at Plants 1-3. The company explained, "While Plants 1-3 maintained stable operations, full operation of Plant 4 made a significant contribution."

Favorable exchange rates also contributed to the improved performance. Contract Development and Manufacturing Organization (CDMO) contracts are typically denominated in dollars. As the Korean won weakens, profits increase when converted to won. Last year, the dollar/won exchange rate averaged around KRW 1,420, up about 4% from the previous year.

Samsung Biologics previously recorded its best-ever performance in 2023, surpassing KRW 1 trillion in operating profit. It was also the first time the company reached the KRW 1 trillion level in annual operating profit. At that time, revenue was KRW 3.6846 trillion and operating profit was KRW 1.1137 trillion, up 23% and 13% year-over-year, respectively.

The company forecasts continued growth this year based on strengthened competitiveness through pure CDMO operations. Samsung Biologics' revenue guidance for this year is KRW 5.32 trillion, approximately 17% higher than last year. This forecast does not include revenue contributions from the acquisition of the Rockville, Maryland plant, and updated projections reflecting related performance will be provided after the acquisition is completed.

Kwon Hae-soon, a researcher at Eugene Investment & Securities, stated, "Long-term contracts with major pharmaceutical companies will continue through expanded production capacity and portfolio, as well as services that meet global clients' supply chain requirements," adding, "Growth momentum will also continue."

Rewritten with generative AI Gemini based on Korea Financial Times content

Rewritten with generative AI Gemini based on Korea Financial Times content

이미지 확대보기

Pure CDMO Competitiveness Highlighted After Spin-off

Attention is focused on the fact that Samsung Biologics' record operating profit was achieved after its spin-off from Samsung Bioepis. Samsung Biologics separated from Samsung Bioepis in November last year and re-launched as a pure CDMO company.

The spin-off was a strategic move to minimize business risks, improve management efficiency, and secure client trust. Due to the nature of the CDMO business, which involves receiving orders from clients to develop and manufacture pharmaceuticals, clients competing with Samsung Biologics' subsidiary Samsung Bioepis might have been hesitant to place orders with Samsung Biologics. However, the spin-off cleanly resolved such conflicts of interest.

The market anticipates Samsung Biologics' growth to continue this year as well. Seo Geun-hee, a researcher at Samsung Securities, analyzed, "While Plant 4 has scheduled temporary operational adjustments for regular maintenance, the impact on profitability is limited," adding, "Solid growth will continue with revenue contributions from increased Plant 5 utilization rates."

He added, "When the U.S. Biosecurity Act takes effect at the end of 2025, 2026 will mark an important turning point when securing volumes from China diversification begins in earnest," noting, "Portfolio diversification is also expected through expansion beyond antibody CMO to next-generation modalities."

At the recent 2026 J.P. Morgan Healthcare Conference (JPMHC), John Rim, CEO of Samsung Biologics, announced a strategy to accelerate the "three-pillar" expansion strategy of production capacity, portfolio, and global presence to become a global top-tier CDMO company.

This includes ▲expansion and diversification of production capacity ▲portfolio expansion encompassing the entire Contract Research Development and Manufacturing Organization (CRDMO) spectrum ▲improved customer satisfaction through expanded global presence.

He also unveiled plans for digital transformation (DX) to innovate biopharmaceutical manufacturing. The plan involves creating an intelligent manufacturing environment through artificial intelligence (AI) and digital twins, and maximizing operational efficiency and manufacturing productivity through data intelligence-based operations and decision-making that learns, understands, and infers data with AI.

CEO John Rim emphasized, "While accelerating the three-pillar expansion strategy, we will strengthen core competencies to continue future growth," adding, "We will further solidify our overwhelming competitive advantage through our core values of '4 Excellence (customer satisfaction, quality competitiveness, operational efficiency, employee capabilities)' and execution strategy of '3S (standardization, simplification, scalability).'"



Yang Hyunwoo (yhw@fntimes.com)

데일리 금융경제뉴스 FNTIMES - 저작권법에 의거 상업적 목적의 무단 전재, 복사, 배포 금지
Copyright ⓒ 한국금융신문 & FNTIMES.com

가장 핫한 경제 소식! 한국금융신문의 ‘추천뉴스’를 받아보세요~

KFT Topic 다른 기사

1 Hanwha Solutions’ Pretax Profit Owes to Asset Sale, Not Core Business Hanwha Solutions’ third-quarter pretax profit turned positive, but the driver was not its core business. It was a single asset sale. The company sold intangible assets with a book value of KRW 12.5 billion and booked a gain of KRW 199.7 billion. Without that gain, this year’s third quarter would show a pretax loss of KRW 176.3 billion.The proceeds from the disposal differ by only KRW 0.8 billion from the amount of fixed assets Hanwha Solutions sold to TransGrid Energy, a Hanwha Group affiliate, over the same period. TransGrid Energy is a subsidiary of a joint venture in which Hanwha Solution 2 Lotte Chemical Pays Down JV Debt With KRW 600 Billion as Its Own Loans Get a Three-Year Reprieve Lotte Chemical contributed KRW 600 billion to help its joint venture H&L Advanced repay existing borrowings. But it has also taken on an impairment loss on its JV shares and faces additional funding support obligations. The value of the shares recognized in the merger-date accounting was less than half the per-share value assessed by an external valuation firm when the merger ratio was set. While pouring large sums into improving the JV’s finances, Lotte Chemical itself has agreed with its creditors to a three-year deferral of repayment on its covenant debt.According to the Financial Supe 3 S-Oil Hits Record Profit, but Shares Sink 40% as Shaheen Bet Looms S-Oil posted record quarterly operating profit in the third quarter of this year, yet its share price has fallen about 40% from its peak.Despite strong results in refining and lubricants, earnings are expected to decline next year. The company also faces the task of proving the profitability of the petrochemical project Shaheen, in which it has invested more than KRW 9 trillion, amid concerns over oversupply.S-Oil reported third-quarter revenue of KRW 11.9687 trillion and operating profit of KRW 1.4067 trillion. Operating profit surged 514% from a year earlier and beat the market consensus by
ad
ad
ad

한국금융 포럼 사이버관

더보기

FT카드뉴스

더보기
[카드뉴스] 성북동 언덕길, 만해의 집을 만나다
[카드뉴스] 약재 향 따라 걷는 서울약령시
[그래픽 뉴스] ‘순대’가 경제용어라고? 순(純)대외자산, 한국의 진짜 해외자산은 얼마일까?
[그래픽 뉴스] ISA 대개편! 나에게 유리한 계좌는?
[그래픽 뉴스] 미국 증시 새로운 키워드 'MANGOS'

FT도서

더보기